CEO SUMMARY: Winston Churchill famously said that “Russia is a riddle wrapped in a mystery inside an enigma.” That description could apply to Theranos, the company that claims it is poised to disrupt the entire clinical laboratory testing industry. In Phoenix, where Theranos is ramping up its clinical lab marketing and operations, competing lab companies have it under the microscope. Some say not all may be going to plan and Theranos has been asked to comment on several issues.
Theranos: Many Questions, but Very Few Answers
Competitors talk about a secretive company and paint a different picture than the one in the media
- By Robert Michel
- | From the Volume XXII No. 6 - April 20, 2015 Issue
- Tags: clia, clia requirements, clinical lab, clinical lab test, clinical lab testing, clinical laboratories, Clinical Laboratory, clinical laboratory scientist, clinical laboratory scientists, clinical laboratory test, clinical laboratory testing, compliance requirements, dark report, diagnostic assays, Diagnostic technology, Elizabeth Holmes, lab executive, lab industry, lab manager, lab managers, lab service, lab services, lab test, lab testing, lab testing services, lab tests, laboratories, laboratory medicine, laboratory scientists, laboratory test, laboratory testing, laboratory testing services, laboratory tests, ldt, Medicare, Medicare Part B, Nanotainer, pathologists, the clinical laboratory, the dark report, Theranos
